Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling by Alessandra Bonito-Oliva et al.
NEUROANATOMY
REVIEW ARTICLE
published: 12 July 2011
doi: 10.3389/fnana.2011.00038
Deciphering the actions of antiparkinsonian and
antipsychotic drugs on cAMP/DARPP-32 signaling
Alessandra Bonito-Oliva, Michael Feyder and Gilberto Fisone*
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
Edited by:
Emmanuel Valjent, Université
Montpellier 1 and 2, France
Reviewed by:
Chip Gerfen, National Institutes of
Health, USA
Michel Cyr, Neuroscience Research
Group, Canada
*Correspondence:
Gilberto Fisone, Department of
Neuroscience, Karolinska Institutet,
Retzius väg 8, 171 77 Stockholm,
Sweden.
e-mail: gilberto.ﬁsone@ki.se
The basal ganglia are affected by several neuropsychiatric and neurodegenerative diseases,
many of which are treated with drugs acting on the dopamine system. For instance, the loss
of dopaminergic input to the striatum, which is the main pathological feature of Parkinson’s
disease, is counteracted by administering the dopamine precursor, L-DOPA. Furthermore,
psychotic disorders, including schizophrenia, are treated with drugs that act as antagonists
at the D2-type of dopamine receptor (D2R). The use of L-DOPA and typical antipsychotic
drugs, such as haloperidol, is limited by the emergence of motor side-effects, particu-
larly after prolonged use. Striatal medium spiny neurons (MSNs) represent an ideal tool to
investigate the molecular changes implicated in these conditions. MSNs receive a large
glutamatergic innervation from cortex, thalamus, and limbic structures, and are controlled
by dopaminergic projections originating in the midbrain.There are two large populations of
striatal MSNs, which differ based on their connectivity to the output nuclei of the basal gan-
glia and on their ability to express dopamine D1 receptors (D1Rs) or D2Rs. Administration
of L-DOPA promotes cAMP signaling and activates the dopamine- and cAMP-regulated
phosphoprotein of 32 kDa (DARPP-32) in the D1R-expressing MSNs, which form the
striatonigral, or direct pathway. Conversely, haloperidol activates the cAMP/DARPP-32 cas-
cade in D2R-expressing MSNs, which form the striatopallidal, or indirect pathway. This
review describes the effects produced on downstream effector proteins by stimulation of
cAMP/DARPP-32 signaling in these twogroups ofMSNs. Particular emphasis is given to the
regulation of the GluR1 subunit of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
glutamate receptor, the extracellular signal-regulated protein kinases 1 and 2, focusing on
functional role and potential pathological relevance.
Keywords: DARPP-32, dopamine D1 receptor, dopamine D2 receptor, ERK, L-DOPA, haloperidol, medium spiny
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Dysfunctions of the dopamine system are implicated inmany neu-
rodegenerative and neuropsychiatric disorders, including Parkin-
son’s disease (PD) and schizophrenia. The cardinal symptoms of
PD (tremor, rigidity, and hypokinesia) are caused by the progres-
sive degeneration of the midbrain dopaminergic neurons of the
substantia nigra pars compacta (Hornykiewicz, 1963; Braak et al.,
2003). These cells project to the dorso-lateral part of the stria-
tum, which is the major component of the basal ganglia, a group
of subcortical nuclei involved in the control of motor function.
The dopamine precursor l-DOPA is widely used in the treatment
of PD (Cotzias et al., 1967; Birkmayer and Hornykiewicz, 1998);
however, prolonged use of this drug is complicated by the appear-
ance of dystonic and choreic movements, or dyskinesia, which are
manifested in parallel with the therapeutic, anti-akinetic action of
l-DOPA (Obeso et al., 2000).
In contrast to PD, schizophrenia and psychotic disorders are
treated with drugs which reduce dopaminergic transmission. In
particular, conventional antipsychotic drugs, such as haloperidol,
act as selective and potent antagonists at D2-type of dopamine
receptors (Creese et al., 1976; Seeman et al., 1976). Even the
use of these substances, however, is limited by the emergence
of motor complications, generally referred to as extrapyramidal
side-effects (EPS), which include tardive dyskinesia, dystonia, and
parkinsonism (Miyamoto et al., 2005).
The development of motor disorders in response to adminis-
tration of l-DOPA and haloperidol depends in large part on the
ability of these drugs to affect transmission in the striatum, which
is enriched in D1- and D2-type of dopamine receptors. The study
of the effects produced in this brain region by antiparkinsonian
and antipsychotic drugs is important not only to elucidate the
mechanisms underlying l-DOPA-induced dyskinesia (LID) and
EPS, but also to examine the impact on motor dysfunctions of
aberrant signaling processes occurring in well-deﬁned neuronal
populations.
DISTINCT ROLES OF STRIATAL MEDIUM SPINY NEURONS IN
MOTOR FUNCTION
In the striatum, ﬁbers originating from midbrain dopaminergic
neurons innervate two populations of principal GABAergic neu-
rons, collectively denominated medium spiny neurons (MSNs).
More than 20 years ago, these two groups of neurons were pro-
posed to form separate projection pathways, exerting opposing
Frontiers in Neuroanatomy www.frontiersin.org July 2011 | Volume 5 | Article 38 | 1
Bonito-Oliva et al. Dopaminergic drugs and striatal signaling
effects on basal ganglia output structures (i.e., substantia nigra
pars reticulata and internal segment of the globus pallidus). It was
suggested that the MSNs directly connected to these structures
would disinhibit thalamo-cortical neurons and promote motor
activity,whereas theMSNs connected to these nuclei indirectly (via
external segment of the globus pallidus and subthalamic nucleus)
would increase the inhibition of efferent targets within the thal-
amus and depress motor function (Albin et al., 1989; Alexander
and Crutcher, 1990; DeLong, 1990).
Another important concept emerging during those years was
that dopamine acted by stimulating the MSNs of the direct, or
striatonigral pathway, and inhibiting those of the indirect, or stri-
atopallidal pathway (Albin et al., 1989; Gerfen et al., 1990). These
opposing effects were suggested to depend on the expression of
dopamine D1 receptors (D1Rs) in the MSNs of the direct pathway
and of dopamine D2 receptors (D2Rs) in the MSNs of the indi-
rect pathway (Gerfen et al., 1990). The hypothesis of a contrasting
action of dopamine on direct and indirect MSNs was supported by
the observation that D1Rs activate, whereas D2Rs inhibit, adeny-
lyl cyclase and cAMP synthesis (Kebabian and Calne, 1979; cf.
below), thereby leading to opposite regulations of downstream
effector targets and neuronal excitability.
The idea that D1Rs and D2Rs are selectively expressed in
distinct groups of MSNs has gained increasing acceptance and,
recently, it has been exploited to revisit and further analyze the
functional properties of the MSNs of the direct and indirect
pathway.
The development of techniques to engineer bacterial artiﬁcial
chromosomes (BACs) has allowed the generation of mice express-
ing Cre recombinase, epitope-tagged proteins, and ﬂuorescent
probes in the D1R- or in the D2R-expressing MSNs of the direct
and indirect pathway (Gong et al., 2003, 2007; Valjent et al., 2009).
Using Cre-dependent viral delivery of channelrhodopsin-2, a light
activated proton pump (Boyden et al., 2005; Kravitz et al., 2010)
demonstrated that optogenetic activation of the D1R-expressing
MSNs of the direct pathway promotes locomotion,whereas activa-
tionof theD2R-expressingMSNsof the indirect pathwaydepresses
motor function.
Another study examined the effects on motor behaviors of
cell-speciﬁc inactivation of the dopamine- and cAMP-regulated
phosphoprotein of 32 kDa (DARPP-32), an important mediator
of cAMP signaling and striatal excitability (Greengard, 2001). It
was found that deletion of DARPP-32 in D1R-expressing MSNs
reduced basal locomotor activity in the open-ﬁeld. In contrast,
inactivation of DARPP-32 in D2R-expressing MSNs increased
locomotion (Bateup et al., 2010). A similar enhancement of motor
function was observed following ablation of striatopallidal MSNs
(Durieux et al., 2009).
DOPAMINE SIGNALING IN STRIATAL MSNs
As previously mentioned, D1Rs and D2Rs mediate opposite reg-
ulations of cAMP signaling. In the striatum, activation of D1Rs
in the direct MSNs leads to Golf-mediated stimulation of adenylyl
cyclase, the enzyme responsible for the synthesis of cAMP (Zhuang
et al., 2000; Herve et al., 2001). The ability of D1Rs to induce G-
protein-dependent activation of cAMP signaling promotes trans-
mission at α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPA; cf. below) and N -methyl-d-aspartate (NMDA) gluta-
mate receptors (Surmeier et al., 1995; Blank et al., 1997; Snyder
et al., 1998; Liu et al., 2004). In addition, D1R-mediated activa-
tion of cAMP signaling increases L-type Ca2+ channel currents
and decreases K+ channel currents (Kitai and Surmeier, 1993;
Surmeier et al., 1995; Galarraga et al., 1997; Gao et al., 1997). These
multiple regulations elevate the ability of sustained release of glu-
tamate to produce depolarized up-states close to spike threshold
(Wickens and Wilson, 1998), thereby promoting the excitability of
striatonigral MSNs (Surmeier et al., 2007).
Activation of D2Rs in the indirect MSNs is coupled to Gi/o-
mediated inhibition of adenylyl cyclase, which decreases cAMP
synthesis (Kebabian and Calne, 1979; Stoof and Kebabian, 1981).
This negative modulation is especially evident on the adenylyl
cyclase type 5 isoform, which is preferentially expressed in stri-
atal MSNs (Glatt and Snyder, 1993; Mons and Cooper, 1994;
Robinson and Caron, 1997). D2R-mediated activation of Gi/o also
leads to decreased cell excitability via G-protein-mediated activa-
tion of inwardly rectifying K+ channels (Wickman et al., 1994;
Greif et al., 1995; Kuzhikandathil et al., 1998; Hopf et al., 2003).
Moreover, D2Rs have been shown to regulate L-type Ca2+ cur-
rents in striatal MSNs through a G-protein- and Ca2+-dependent
mechanism which does not require suppression of cAMP signal-
ing (Hernandez-Lopez et al., 2000). The coordinated modulation
of ion channels exerted by D2R via activation of Gi/o protein
leads to reduced responsiveness of striatopallidal MSNs to glu-
tamate, diminished transition of MSNs to depolarized up-states
and reduced excitability (Surmeier et al., 2007).
In summary, the opposite regulation exerted by D1Rs and
D2Rs on the responsiveness of MSNs to glutamate is in line with
the functional model of basal ganglia described above, in which
dopamine promotes motor activity via concomitant activation of
direct MSNs and inhibition of indirect MSNs (Albin et al., 1989;
Alexander and Crutcher, 1990; DeLong, 1990; Surmeier et al.,
2007).
L-DOPA AND HALOPERIDOL IN THE STRIATUM: FOCUS ON
cAMP SIGNALING IN MSNs
Studies performed in experimental models of PD indicate that
administration of l-DOPA results in multiple changes in signal
transduction, which occur speciﬁcally in the MSNs of the direct
pathway. These changes depend on the loss of striatal dopamine,
which results in the development of a remarkable sensitization at
striatal D1Rs (Guigoni et al., 2005; Santini et al., 2008). Such sen-
sitization potentiates the ability of l-DOPA to promote cAMP sig-
naling, leading to stimulation of cAMP-dependent protein kinase
(PKA) and phosphorylation of DARPP-32 (Picconi et al., 2003;
Santini et al., 2007, 2010; Lebel et al., 2010). As discussed below,
prolonged activation of this signaling cascade is implicated in the
development of LID.
In contrast to l-DOPA, the actions of antipsychotic drugs (e.g.,
haloperidol) in the striatum are generally attributed to their abil-
ity to antagonize D2Rs on the MSNs of the indirect pathway. The
primary effect of D2R blockade is the removal of the inhibition
exerted by theGi/o protein on adenylyl cyclase, leading to increased
cAMP signaling. This effect, in turn, depends on basal adenylyl
cyclase activity, which is maintained through the action of the
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neuromodulator adenosine. The MSNs of the indirect pathway
express high levels of adenosine A2A receptors (A2ARs; Schiff-
mann et al., 1991; Fink et al., 1992), which, similarly to D1Rs,
are coupled to Golf-mediated activation of adenylyl cyclase (Kull
et al., 2000; Herve et al., 2001). Thus, in the MSNs of the indirect
pathway,D2Rs andA2ARs exert opposite regulations on cAMPsig-
naling. An important consequence of this functional arrangement
is that blockade of A2AR-mediated transmission prevents the abil-
ity of D2R antagonists, including haloperidol, to increase cAMP
signaling in indirect MSNs (Svenningsson et al., 2000; Håkansson
et al., 2006; Bertran-Gonzalez et al., 2009; cf. Figure 1).
In summary, both l-DOPA and haloperidol promote cAMP-
dependent signaling in striatal MSNs. The effect of l-DOPA is
exerted in the MSNs of the direct pathway, via D1R-mediated acti-
vation of adenylyl cyclase. In contrast, the effect of haloperidol is
exerted on the MSNs of the indirect pathway through blockade of
D2Rs and disinhibition of adenylyl cyclase (Figure 1).
DARPP-32: A MEDIATOR OF THE ACTIONS OF
ANTIPARKINSONIAN AND ANTIPSYCHOTIC DRUGS
The ability of l-DOPA and haloperidol to promote cAMP sig-
naling is reﬂected by the large increase in the phosphorylation of
DARPP-32 produced by administration of these drugs. DARPP-32
is highly expressed in the MSNs of the direct and indirect pathway
and plays an important role in dopamine transmission (Fien-
berg et al., 1998; Greengard, 2001). Activation of D1Rs in direct
FIGURE 1 | Diagram summarizing the effects produced by L-DOPA and
haloperidol on cAMP signaling in the striatal MSNs of the direct and
indirect pathway. In PD, loss of dopamine in the striatum leads to increased
responsiveness of D1Rs, expressed in the direct MSNs of the striatonigral
pathway. Administration of L-DOPA increases the production of dopamine and
activates D1Rs, which stimulate the cAMP/PKA pathway, thereby
phosphorylating DARPP-32 (D32) at Thr34 (Picconi et al., 2003; Santini et al.,
2007, 2010). A similar effect is produced by haloperidol in the indirect MSNs
of the striatopallidal pathway via blockade of D2Rs and disinhibition of
A2AR-mediated activation of cAMP signaling (Svenningsson et al., 2000). The
activation of the PKA/DARPP-32 cascade produced by L-DOPA and
haloperidol increases the phosphorylation of targets located in the
cytoplasm/plasma membrane, such as the GluR1 subunit of the glutamate
AMPA receptor (Håkansson et al., 2006; Santini et al., 2007). In direct MSNs,
L-DOPA promotes ERK signaling. This effect may be exerted via
PKA/DARPP-32-mediated regulation of Ras-GRF1 (Mattingly, 1999) and/or
striatal-enriched protein tyrosine phosphatase (Valjent et al., 2005), which are
involved in the regulation of ERK phosphorylation. ERK-dependent activation
of MSK1 results in phosphorylation of histone H3 at Ser10 and enhanced
expression of c-fos (Santini et al., 2007). Activation of ERK also increases the
expression of zif268 and fosB, which has been associated to LID
(Andersson et al., 1999; Carta et al., 2005). Increased FosB, in turn, leads to
enhanced levels of dynorphin (Andersson et al., 1999). In the indirect
striatopallidal MSNs, the regulation of histone H3 and gene expression
exerted by haloperidol occurs independently of the ERK/MSK1 cascade. Thus,
histone H3 is regulated via PKA-catalyzed phosphorylation and by
concomitant suppression of dephosphorylation, via DARPP-32-mediated
inhibition of PP-1 (Bertran-Gonzalez et al., 2009). In addition, the ability of
haloperidol to activate PKA leads to increased phosphorylation of the
cAMP-response element binding protein (CREB), which may be involved in
the control of Fos expression (Konradi and Heckers, 1995). The control of
multiple signaling pathways exerted by L-DOPA and haloperidol in the MSNs
of the direct and indirect pathway may ultimately modify the activity of these
neuronal populations, leading to abnormal motor responses, including
L-DOPA-induced dyskinesia and extrapyramidal side-effects. Broken lines
indicate indirect effects. See text for abbreviations.
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MSNs increases PKA-dependent phosphorylation of DARPP-32
on Thr34 (Nishi et al., 1997; Svenningsson et al., 1998). A similar
effect is produced by activation of A2ARs in indirect MSNs (Sven-
ningsson et al., 1998). Phosphorylation of Thr34 converts DARPP-
32 into an inhibitor of protein phosphatase-1 (PP-1; Hemmings
et al., 1984), which ampliﬁes the effects of the cAMP/PKA cascade
by reducing dephosphorylation of downstream target proteins
(Fienberg et al., 1998; Greengard, 2001; cf. Figure 1).
In the dopamine depleted striatum, administration of l-DOPA
increases the phosphorylation of DARPP-32 at Thr34 (Picconi
et al., 2003; Santini et al., 2007, 2010; Lebel et al., 2010). In rodent
and non-human primate models of PD, this effect is associated
to the manifestation of abnormal involuntary movements, which
are regarded as a behavioral correlate of dyskinesia (Cenci et al.,
2002). In line with these observations, it has been shown that LID
is attenuated in DARPP-32 knock out mice (Santini et al., 2007).
Interestingly, a large reduction of LID has also been observed in
mice in which DARPP-32 is speciﬁcally inactivated in the MSNs
of the direct pathway, whereas deletion of DARPP-32 in indi-
rect MSNs does not affect the development of dyskinesia (Bateup
et al., 2010). These ﬁndings indicate the importance of enhanced
D1R/PKA/DARPP-32 signaling in LID and identify the MSNs of
the direct pathway as a key neuronal substrate implicated in this
condition.
Administration of D2R antagonists, including haloperidol,
promotes PKA-dependent phosphorylation of DARPP-32 (Sven-
ningsson et al., 2000). This effect is produced via disinhibition of
adenylyl cyclase, whose basal activation is maintained by A2ARs
(cf. above). In support of this idea, it has been shown that both
pharmacological and genetic inactivation of A2ARs prevent the
increase in DARPP-32 phosphorylation induced by eticlopride,
a potent D2R antagonist (Svenningsson et al., 2000). The effect
of haloperidol has been examined in BAC transgenic mice over-
expressing DARPP-32 with different epitope tags in D1R- or
D2R-expressing MSNs (Bateup et al., 2008). In these animals,
tag-speciﬁc immunoprecipitation of DARPP-32 indicates that the
increase in Thr34 phosphorylation induced by haloperidol occurs
speciﬁcally in the D2R-expressing MSNs of the indirect pathway
(Bateup et al., 2008).
Other studies examined the role of DARPP-32 in the changes
of motor activity produced by haloperidol. Blockade of D2Rs
results in a state of rigid immobility, or catalepsy, which repre-
sents a surrogate marker of EPS. This form of motor depression
is thought to reﬂect the ability of haloperidol and other D2R
antagonists to activate indirect MSNs, through removal of the
inhibition exerted on these neurons by D2Rs (cf. above; Albin
et al., 1989; Alexander and Crutcher, 1990; DeLong, 1990; Ger-
fen et al., 1990). Activation of the MSNs of the indirect path-
way would lead, in turn, to inhibition of thalamo-cortical neu-
rons (Albin et al., 1989; Alexander and Crutcher, 1990; DeLong,
1990; Gerfen et al., 1990) and reduction of motor cortex activ-
ity (Parr-Brownlie and Hyland, 2005). Deletion of DARPP-32 in
indirect MSNs decreases haloperidol-induced catalepsy, whereas
DARPP-32 inactivation in direct MSNs only slightly affects this
behavioral response (Bateup et al., 2010). These ﬁndings indi-
cate the importance of the PKA/DARPP-32 signaling pathway in
haloperidol-induced motor depression and point to the MSNs of
the indirect pathway as a critical neuronal population involved
in EPS.
REGULATION OF GluR1 PHOSPHORYLATION
Activation of the cAMP/PKA/DARPP-32 cascade increases the
phosphorylation of the GluR1 subunit of the AMPA glutamate
receptor (Banke et al., 2000; Snyder et al., 2000). Phosphorylation
of GluR1 at the PKA site, Ser845,promotes glutamate transmission
by increasing AMPA channel currents (Roche et al., 1996; Banke
et al., 2000) and enhancing cell surface expression of the receptor
(Mangiavacchi and Wolf, 2004). In the dopamine depleted stria-
tum, l-DOPA enhances Ser845 phosphorylation and this effect
has been associated to LID in both mice and monkeys (Santini
et al., 2007, 2010). Indeed, GluR1 hyperphosphorylation may be
causally linked to dyskinesia, which is currently treated with drugs
that reduce glutamatergic transmission (Goetz et al., 2005).
GluR1 phosphorylation at Ser845 is also increased by admin-
istration of haloperidol (Håkansson et al., 2006). This effect
depends on disinhibition of PKA in indirect MSNs, since it is
abolished by pre-treatment with an A2AR antagonist (cf. above;
Håkansson et al., 2006). In addition, haloperidol fails to phos-
phorylate GluR1 in DARPP-32 knock out mice, or in mice in
which the PKA phosphorylation site of DARPP-32 (i.e., Thr34)
is replaced with an alanine (T34A mutant mice; Håkansson et al.,
2006). Thus, in indirect MSNs, haloperidol increases the phos-
phorylation of the AMPA glutamate receptor via activation of the
cAMP/PKA/DARPP-32/PP-1 cascade. In view of the permissive
role played by PKA-dependent phosphorylation of GluR1 on glu-
tamatergic transmission (Roche et al., 1996; Banke et al., 2000;
Mangiavacchi and Wolf, 2004), this effect of haloperidol is likely
to promote the excitability of indirect MSNs, thereby leading to
motor depression and, possibly, to the generation of EPS.
The activation of cAMP signaling produced by l-DOPA and
haloperidol in direct and indirect MSNs is involved in the behav-
ioral responses associated to these drugs. However, the increases in
DARPP-32 and GluR1 phosphorylation discussed above are tran-
sient, whereas LID and EPS are most likely caused by long-term
adaptive responses involving dysregulated gene expression.
DOWNSTREAM OF THE cAMP/DARPP-32 CASCADE I.
EFFECTS OF L-DOPA IN DIRECT MSNs
Seminal studies carried out by Gerfen et al. (1990) in 6-OHDA-
lesioned rats showed that, in the striatum, dopamine deafferenta-
tion decreased the transcription of mRNA coding for substance
P, a neuropeptide speciﬁcally expressed in the direct MSNs. Con-
versely, the 6-OHDA lesion increased the levels of mRNA coding
for the neuropeptide enkephalin, which is expressed in indirect
MSNs (Gerfen et al., 1990). In addition to these changes, which
reﬂect the opposite regulation exerted by dopamine on direct and
indirect MSNs (cf. above), it was found that repeated administra-
tion of a D1R agonist increased mRNA for dynorphin, speciﬁcally
in direct MSNs (Gerfen et al., 1990). Later studies in the same
experimental model showed that a similar increase in dynorphin
expression occurs also in response to chronic administration of
l-DOPA and that this effect correlates with the severity of abnor-
mal involuntary movements (i.e., dyskinesia) produced by this
drug (Andersson et al., 1999). These observations prompted the
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investigation of the mechanisms mediating the modiﬁcations in
the expression of dynorphin and other genes potentially involved
in LID.
The extracellular signal-regulated protein kinases 1 and 2
(ERK) have emerged as key signaling components involved in
the control of gene expression and synaptic plasticity (Thomas
and Huganir, 2004). In the striatum, ERK signaling has been
implicated in the actions of addictive drugs and in corticos-
triatal long-term potentiation (Valjent et al., 2000, 2005; Xie
et al., 2009). Stimulation of the D1R/PKA/DARPP-32 cascade
leads to the phosphorylation and activation of ERK (Valjent
et al., 2005; Santini et al., 2007; but see also Gerfen et al., 2008),
which controls a variety of downstream effector proteins in the
nucleus and cytoplasm (Thomas and Huganir, 2004). In the
dopamine depleted striatum,activation of D1Rs or administration
of l-DOPA increase the phosphorylation of ERK and its nuclear
target,mitogen- and stress-activated kinase 1 (MSK1;Gerfen et al.,
2002; Pavon et al., 2006; Santini et al., 2007, 2009; Westin et al.,
2007). This, in turn, leads to phosphorylation of histone H3 at
Ser10 (Santini et al., 2007, 2009; Darmopil et al., 2009), which is
thought to promote transcriptional activation (Nowak andCorces,
2004).
Evidence obtained in rodent and monkey models show that
activation of ERK signaling is implicated in LID (Santini et al.,
2007; Schuster et al., 2008; Fasano et al., 2010). Studies in
BAC transgenic mice expressing enhanced green ﬂuorescent pro-
tein (EGFP) under the control of the promoter for either the
D1R (drd1a-EGFP mice) or the D2R (drd2-EGFP mice; San-
tini et al., 2009) indicate that activation of the ERK/MSK1/H3
cascade occurs selectively in the D1R-containing MSNs of the
direct pathway (Santini et al., 2009). Therefore, it is likely
that, in these neurons, abnormal activation of PKA/DARPP-32
and ERK signaling in response to l-DOPA promotes transcrip-
tional responses ultimately responsible for the development of
dyskinesia.
Chronic administration of cocaine, a drug which promotes
dopaminergic transmission, leads to the accumulation of stable,
alternatively spliced isoforms of the transcription factor FosB, gen-
erally denominated as FosB (Hope et al., 1994; Nestler et al.,
2001). EnhancedFosB levels have been also observed in the stri-
ata of rodent and non-human primate models of PD following
chronic administration of l-DOPA (Andersson et al., 1999; Pavon
et al., 2006; Berton et al., 2009; Fasano et al., 2010), as well as
in postmortem samples from parkinsonian patients treated with
l-DOPA (Tekumalla et al., 2001).
Interestingly, the ability of l-DOPA to increase FosB expres-
sion correlates with the emergence of dyskinesia (Doucet et al.,
1996; Andersson et al., 1999; Pavon et al., 2006; Berton et al., 2009;
Fasano et al., 2010). This effect is produced in response to acti-
vation of D1Rs (Doucet et al., 1996; Darmopil et al., 2009) and
is restricted to the MSNs of the direct pathway (Andersson et al.,
1999;Darmopil et al., 2009),where activation of ERK is also occur-
ring (Darmopil et al., 2009; Santini et al., 2009). Thus, in mice
and monkeys, the increase in FosB associated to LID is abol-
ished by inactivation of Ras-guanine nucleotide-releasing factor 1
(Ras-GRF1), a brain speciﬁc component of the Ras-ERK signaling
cascade (Fasano et al., 2010).
Several lines of evidence indicate that overexpression ofFosB
is implicated in LID. Experiments performed in 6-OHDA-lesioned
rats showed that downregulation of FosB, achieved by striatal
injection of a fosB antisense oligonucleotide, decreases l-DOPA-
induced abnormal involuntary movements (Andersson et al.,
1999). A similar effect has been recently observed in the macaque
following viral-induced overexpression of JunD, a dominant
negative of FosB (Berton et al., 2009; Cao et al., 2010). Further-
more, in the rat, LID is reduced or exacerbated by overexpression
of JunD andFosB, respectively (Cao et al., 2010).
Taken together, the studies described above indicate that LID is
produced by sensitized D1R transmission, which leads to cAMP-
dependent activationof ERK/MSK1 signaling. This, in turn, results
in enhanced phosphorylation of histoneH3 at Ser10 and increased
expression of the transcription factor FosB (Figure 1). One
important task for future studies will be the identiﬁcation of spe-
ciﬁc sets of genes regulated by this intracellular pathway. In this
regard it is interesting to note that the increase in dynorphin asso-
ciated to LID has been shown to depend on the ability of chronic
l-DOPA to induceFosB (Andersson et al., 1999).
DOWNSTREAM OF THE cAMP/DARPP-32 CASCADE II.
EFFECTS OF HALOPERIDOL IN INDIRECT MSNs
As discussed above, the changes in gene expression associated to
LID are primarily linked to the ability of l-DOPA to act on sensi-
tizedD1Rs, leading to sequential activationof PKA/DARPP-32 and
ERK signaling (Pavon et al., 2006; Santini et al., 2007, 2008;Westin
et al., 2007; Lebel et al., 2010). Administration of haloperidol and
other D2R antagonists is also known to induce the expression
of several immediate early genes acting as transcription factors,
including c-fos, fosB, and zif268 (Dragunow et al., 1990; Miller,
1990; Robertson and Fibiger, 1992; MacGibbon et al., 1994, 1995).
This effect is particularly evident in the dorsal striatum and has
been correlated to the propensity of antipsychotic drugs to induce
EPS (Robertson and Fibiger, 1992; MacGibbon et al., 1994).
The increase in c-fos expression produced by haloperidol
occurs selectively in the enkephalin-positive MSNs of the indi-
rect pathway (Robertson et al., 1992). Recent work in drd1a- and
drd2-EGFP mice has conﬁrmed this initial observation, show-
ing that haloperidol increases c-Fos and Zif268 speciﬁcally in
D2R-expressing MSNs (Bertran-Gonzalez et al., 2008).
The control exerted by haloperidol on gene expression depends
on the ability of this drug to promote cAMP signaling by antago-
nizing D2R-mediated transmission (cf. above). In support of this
idea, it has been shown that genetic inactivation of the regula-
tory IIβ subunit of PKA, which is highly expressed in the striatum
(Cadd and McKnight, 1989), abolishes the effect of haloperidol
on c-fos expression (Adams et al., 1997). In line with this obser-
vation, intrastriatal injection of antisense oligonucleotides against
the cAMP-response element binding protein, a transcription fac-
tor activated by PKA, prevents haloperidol-mediated induction of
c-Fos protein (Konradi and Heckers, 1995). Other studies showed
that the increase in enkephalin mRNA produced by acute and
chronic administration of haloperidol is reduced in the absence of
A2ARs, which are necessary to maintain normal cAMP signaling
in the striatal MSNs of the indirect pathway (cf. above; Chen et al.,
2001). Interestingly, the ability of haloperidol to induce catalepsy
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is also attenuated in both PKA- and A2AR-deﬁcient mice (Adams
et al., 1997; Chen et al., 2001), suggesting that reduced cAMP
signaling in indirect MSNs may attenuate EPS.
The ability of haloperidol to promote cAMP/DARPP-32 signal-
ing is accompanied by increased ERK phosphorylation in a small
number of MSNs belonging to the indirect pathway (Bertran-
Gonzalez et al., 2008, 2009). This modest effect contrasts with
the relatively large increase in ERK phosphorylation detected in
striatal tissue by western blotting (Pozzi et al., 2003). In fact, a
considerable proportion of the increase in ERK phosphorylation
produced by haloperidol is conﬁned to the terminals of midbrain
dopaminergic neurons. In support of this possibility it has been
shown that, in the striatum, haloperidol increases ERK-dependent
phosphorylation of tyrosine hydroxylase, whose localization is
restricted to dopaminergic ﬁbers (Håkansson et al., 2004). This
effect may be secondary to the block exerted by haloperidol on
inhibitory dopamine D2 autoreceptors located on cell bodies and
terminals of nigrostriatal dopaminergic neurons (Håkansson et al.,
2004; Fisone et al., 2007).
Administration of haloperidol results in a large increase in
phosphorylation of histone H3 at Ser10, which occurs in the D2R-
expressing MSNs of the indirect pathway (Bertran-Gonzalez et al.,
2008, 2009). This effect differs from the more restricted and mod-
est increase in ERK phosphorylation (cf. above; Bertran-Gonzalez
et al., 2008, 2009), suggesting that ERK signaling is not involved
in the phosphorylation of histone H3 produced by blockade of
D2Rs. This idea is conﬁrmed by the observation that neither
pharmacological inhibition of ERK, nor genetic inactivation of
MSK1,affects haloperidol-inducedphosphorylationof histoneH3
(Bertran-Gonzalez et al., 2009).
Several lines of evidence indicate that the ability of D2R antag-
onists, including antipsychotic drugs, to promote histone H3
phosphorylation at Ser10 depends exclusively on activation of the
cAMP/DARPP-32 cascade. For instance, the ability of haloperidol
to increase the levels of phospho-Ser10-Lys14-acetylated histone
H3 is prevented by blockade of PKA (Li et al., 2004). A similar
effect has been observed following genetic attenuation of the Golf
protein, which couples A2ARs to activation of adenylyl cyclase
(Kull et al., 2000; Herve et al., 2001), or pharmacological blockade
of A2ARs (Bertran-Gonzalez et al., 2009). Finally, the ability of
haloperidol to regulate histone H3 also requires PKA-dependent
activation and nuclear translocation of DARPP-32 (Stipanovich
et al., 2008; Bertran-Gonzalez et al., 2009). Thus, in striatopallidal
MSNs, the PKA/DARPP-32 signaling pathway regulates histone
H3 phosphorylation independently of the ERK/MSK1 cascade,
which is generally thought to be critically involved in the gen-
eration of the nucleosomal response (Thomson et al., 1999;
Figure 1).
CONCLUSION
The advent of sophisticated methodological approaches based on
the use of BAC transgenic mice (Heintz, 2001) and optogenetics
(Deisseroth, 2011) has allowed a reﬁned analysis of the circuitries
and mechanisms involved in a multitude of physiopathological
conditions. In this regard, the striatal MSNs of the direct and indi-
rect pathway have represented a particularly interesting subject of
study. These neurons are the primary target of medications used
in the treatment of PD and schizophrenia and are distinguishable
based on the organization of their connectivity within the basal
ganglia and of their ability to express distinct sets of neurotrans-
mitter receptors (Albin et al., 1989; Gerfen et al., 1990). This latter
feature has made it possible to generate transgenic mice in which
the physiological properties of direct and indirect MSNs, as well as
their ability to respond to a variety of psychoactive substances, can
be examined by cell-speciﬁc genetic manipulations (Gong et al.,
2003, 2007; Valjent et al., 2009).
This review focused on the changes in signal transduction
produced in striatal MSNs by l-DOPA and haloperidol, with par-
ticular emphasis on the potential involvement of these changes
in the movement disorders caused by prolonged use of these
drugs. The emerging picture indicates that LID and EPS are
caused by dysregulation of cAMP signaling in direct and indi-
rect MSNs, respectively. In line with this idea, increased activity
of PKA and DARPP-32 in these two groups of neurons has been
implicated in l-DOPA- and haloperidol-induced motor disorders
(Santini et al., 2007; Bateup et al., 2010). The activation of the
PKA/DARPP-32 signaling cascade produced by administration
of l-DOPA and typical antipsychotic drugs leads to chromatin
modiﬁcations (e.g., histone H3 phosphorylation at Ser10) and to
the expression of several immediate early genes acting as tran-
scription factors (e.g., fos-c, fosB/fosB, and zif268; Figure 1).
Future studies will be necessary to examine the relative con-
tribution of these various responses to the development and
manifestation of LID and EPS. It will also be essential to iden-
tify molecular targets regulated by this complex transcriptional
machinery and evaluate their possible involvement in aberrant
motor behaviors.
An intriguing point emerging from recent studies concerns
the existence of distinct mechanisms by which l-DOPA and
haloperidol promote nucleosomal response and gene expression
in striatal MSNs. In the case of l-DOPA, these effects require
D1R/PKA/DARPP-32-mediated activation of ERK/MSK1 signal-
ing. Thus, pharmacological or genetic inactivation of ERK pre-
vents the increase in gene expression and the phosphorylation
of histone H3 induced by l-DOPA and associated to LID (San-
tini et al., 2007; Fasano et al., 2010). In contrast, the ability of
haloperidol to modify histone H3 and gene expression does not
appear to involve activation of ERK signaling. This is indicated by
the modest effect on ERK phosphorylation produced by haloperi-
dol in striatal MSNs and, most importantly, by the observation
that genetic inactivation of MSK1 does not affect the ability of
haloperidol to phosphorylate histone H3 (Bertran-Gonzalez et al.,
2009).
Taken together, the above observations indicate that cAMP-
dependent regulation of long-term responses in direct and indi-
rect MSNs engages, at least in part, different signaling pathways
(Figure 1). This distinction may be exploited to design therapeutic
approaches tailored to counteract motor disturbances produced
by dysfunctional signaling in one or the other neuronal popula-
tion. For instance, drugs interfering with ERK signaling may be
particularly suited for the treatment of LID and less efﬁcacious
to counteract EPS, since haloperidol produces only a modest acti-
vation of the ERK/MSK1 cascade in indirect MSNs. Indeed, it
has been shown that administration of ERK inhibitors, or genetic
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inactivation of Ras-GRF1, reduce LID in animal models of PD
(Santini et al., 2007; Fasano et al., 2010). Further work on the char-
acterization of signal transduction in direct and indirect MSNs
will open new vistas on the functioning of the striatum in physi-
ological and pathological conditions and provide information for
the treatment of diseases caused by altered transmission in this
brain region.
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